|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics Reports Interim Data for COPD Stem Cell Study
06-23-09
15.6 KB
|
| |
COLUMBIA, Md., Jun 23, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced six-month
interim data from a Phase II clinical trial evaluating Prochymal, the
Company's proprietary formulation of adult mesenchymal stem cells, for
the treatment of chronic obstructive pulmonary disease (COPD). Sixty-two...
|
|
Osiris Therapeutics to Present at Piper Jaffray Conference
06-17-09
11.7 KB
|
| |
COLUMBIA, Md., Jun 17, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell
therapeutic company focused on developing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and CEO, is
sche...
|
|
Osiris Therapeutics to Present at Eighth Annual JMP Securities Research Conference
05-13-09
11.8 KB
|
| |
COLUMBIA, Md., May 13, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell
therapeutic company focused on developing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and CEO, is
sche...
|
|
Osiris Therapeutics Reports First Quarter 2009 Financial Results
05-07-09
23.0 KB
|
| |
COLUMBIA, Md., May 07, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell
therapeutic company focused on developing and marketing products to
treat medical conditions in the inflammatory, cardiovascular and
orthopedic areas, announced today its financial results for the first
quart...
|
|
Osiris Therapeutics Announces First Quarter 2009 Financial Results Conference Call
04-27-09
13.6 KB
|
| |
COLUMBIA, Md., Apr 27, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced that it will report
its financial results for the quarter ended March 31, 2009, on Thursday,
May 7, 2009. C. Randal Mills, Ph.D., President and Chief Executive
Officer, and Richard Hunt, Chief Financial Officer, wil...
|
|
Osiris Completes Enrollment in Second Prochymal Phase III Trial for Graft vs. Host Disease
04-17-09
14.8 KB
|
| |
COLUMBIA, Md., Apr 17, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has
successfully completed patient enrollment in its pivotal, Phase III
trial evaluating Prochymal
as a first-line treatment for acute graft vs. host disease (GvHD), a
life-threatening complication o...
|
|
First Patient Treated in Osiris Phase II Stem Cell Trial for Heart Attacks
04-02-09
13.1 KB
|
| |
COLUMBIA, Md., Apr 02, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the treatment of
the first patient in a Phase II clinical trial evaluating Prochymal for
the treatment of heart attacks. The first patient, a 58-year old man,
was treated at the Heart Hospital of Austin, Texas.
Prochymal i...
|
|
Osiris Therapeutics Announces Accelerated Transfer of Osteocel Product Line
03-30-09
11.9 KB
|
| |
COLUMBIA, Md., Mar 30, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has
agreed with NuVasive, Inc. (NASDAQ:NUVA) to accelerate transfer of the
Osteocel business. Under the terms of amendments to the existing Asset
Purchase and Manufacturing agreements between the parties, NuVasive w...
|
|
Osiris Discontinues Enrollment in Crohn's Study Due to Concerns with Trial Design
03-27-09
14.4 KB
|
| |
COLUMBIA, Md., Mar 27, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today that it has
elected to end enrollment at 210 patients in its Phase III trial
evaluating Prochymal for Crohn's disease. The Company believes there is
a design flaw in the trial resulting in significantly higher than
...
|
|
Osiris Therapeutics to Present at Barclays Capital Global Healthcare Conference
03-03-09
11.8 KB
|
| |
COLUMBIA, Md., Mar 03, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell
therapeutic company focused on developing and marketing products to
treat medical conditions in the inflammatory, orthopedic and
cardiovascular areas, announced today that C. Randal Mills, Ph.D.,
President an...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
